Stocks of Stoke Therapeutics Inc (NASDAQ:STOK) traded higher last session on Wall Street, up 37.71% to $14.17.
STOK stock price is now 141.19% away from the 50-day moving average and 135.13% away from the 200-day moving average. The market capitalization of the company currently stands at $632.69M.
, while ‘TD Cowen’ rates the stock as ‘Market Perform’
In other news, Kaye Edward M. MD, CEO sold 11,150 shares of the company’s stock on Mar 19 ’24. The stock was sold for $67,999 at an average price of $6.10. Upon completion of the transaction, the CEO now directly owns 69,350 shares in the company, valued at $0.98 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 19 ’24, CHIEF MEDICAL OFFICER Ticho Barry sold 4,116 shares of the business’s stock. A total of $25,102 was realized by selling the stock at an average price of $6.10. This leaves the insider owning 11,469 shares of the company worth $0.16 million. A total of 37.83% of the company’s stock is owned by insiders.
During the past 12 months, Stoke Therapeutics Inc has had a low of $3.35 and a high of $14.00. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 6.99, and a quick ratio of 6.99. The fifty day moving average price for STOK is $6.06 and a two-hundred day moving average price translates $6.04 for the stock.
The latest earnings results from Stoke Therapeutics Inc (NASDAQ: STOK) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.6, beating analysts’ expectations of -$0.63 by 0.03. This compares to -$0.65 EPS in the same period last year. The net profit margin was -1192.34% and return on equity was -60.80% for STOK. The company reported revenue of $2.8 million for the quarter, compared to $3.27 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -14.32 percent. For the current quarter, analysts expect STOK to generate $3.21M in revenue.
